Vanuatu
Tuberculosis profile
Population  2013 <1 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.016 (<0.01–0.033) 6.3 (2.3–13)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 0.21 (0.094–0.38) 84 (37–151)
Incidence  (includes HIV+TB) 0.16 (0.13–0.19) 62 (51–74)
Incidence (HIV+TB only)        
Case detection, all forms (%) 78 (65–95)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0 (0–12) 24 (20–27)
MDR-TB cases among notified pulmonary
TB cases
0 (0–8) 0 (0–0)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 42   1
Pulmonary, clinically diagnosed 24   0
Extrapulmonary 56   0
       
Total new and relapse 123    
Previously treated, excluding relapses 0    
Total cases notified 123    
Among 123 new and relapse cases:
24 (20%) cases aged under 15 years; male:female ratio: 0.9
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 0 (0%) 0 (0%) 0
Laboratory-confirmed RR-/MDR-TB cases     0
Patients started on MDR-TB treatment     0
TB/HIV 2013 Number (%)
TB patients with known HIV status 59 (48)
HIV-positive TB patients 0 (0)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0  
HIV-positive TB patients on antiretroviral therapy (ART) 0  
HIV-positive people screened for TB 2  
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 91
Previously treated cases, excluding relapse, registered in 2012 100
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 4.4
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) <1
% Funded domestically 83%
% Funded internationally 16%
% Unfunded 1%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-05-23 Data: www.who.int/tb/data